Axoft Secures $55M for Ultra-Soft Brain Implants, Peel Therapeutics Nabs $20M for Anti-Cancer Nanoparticles in Series A Funding

August 23, 2026

Acquirezy USA

Overview

US nanotechnology companies Axoft and Peel Therapeutics have secured significant Series A funding rounds totaling $75 million between April and May 2026. Axoft raised $55 million for its ultra-soft brain implants designed for brain activity recording and neurological disease treatment, while Peel Therapeutics garnered $20 million for its anti-cancer protein nanoparticle technology aimed at targeted cancer therapy. These investments underscore robust investor confidence in the commercial and clinical promise of nanotechnology in high-impact medical applications.

In Depth

Background

In recent years, nanotechnology has driven revolutionary advancements in the medical field, particularly in drug delivery, diagnostics, and implant technologies. Ultra-soft brain implants are garnering significant attention in the field of Brain-Machine Interfaces (BMIs). By precisely capturing and stimulating brain signals, they are expected to contribute to functional recovery in paralyzed patients and alleviate symptoms of neurological disorders. Meanwhile, the use of nanoparticles in cancer treatment is advancing as a crucial approach to enhance the precision of targeted therapies and realize personalized medicine. These sectors are characterized by significant unmet medical needs and high growth potential, leading to active investment from venture capital firms.

Key Findings

Between April and May 2026, two U.S. nanotechnology startups successfully closed Series A funding rounds totaling $75 million (approximately 10 billion JPY). Axoft secured $55 million for its ultra-soft brain implant technology, and Peel Therapeutics raised $20 million for its anti-cancer protein nanoparticle technology, accelerating innovation in nanomedicine and bioelectronics.

Technical and Clinical Details

Axoft’s ultra-soft brain implants are engineered to enable precise recording of brain activity, aiming to support the diagnosis and treatment of neurological disorders. Compared to existing rigid electrodes, these implants are expected to minimize damage to brain tissue and enhance long-term biocompatibility. This technology holds the potential to open new avenues for treating neurodegenerative and neuropsychiatric conditions such as Parkinson’s disease, epilepsy, and Alzheimer’s disease.

Peel Therapeutics’ anti-cancer protein nanoparticles are designed to target specific cancer cells, aiming to enhance therapeutic efficacy while reducing side effects compared to conventional chemotherapy. These nanoparticles could efficiently deliver drugs directly to tumor sites, minimizing exposure to healthy cells and potentially offering safer and more effective cancer treatments.

Future Outlook

This Series A funding represents a critical step for both Axoft and Peel Therapeutics to accelerate clinical development and further mature their respective technologies. Axoft’s brain implants could, in the future, be applied to early diagnosis of brain disorders, real-time monitoring, and more effective neurostimulation therapies. Peel Therapeutics’ nanoparticle therapy is expected to offer new treatment options for various types of cancer, improving patients’ quality of life. These nanotechnology-driven innovations are poised to play an indispensable role in shaping the future of medicine.

Source: https://castleplacement.com/top-10-nanotech-capital-raises-and-investors-in-the-u-s-april-1st-may-31st-2026/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.